Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 210,148,116 papers from all fields of science
Search
Sign In
Create Free Account
NUDCD1 gene
Known as:
NUDCD1
, NUDC DOMAIN-CONTAINING PROTEIN 1
, NudC domain containing 1
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
Genes
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Aberrant expression of long non-coding RNAs (lncRNAs) is involved in brain glioma development
Yi Ding
,
Xinfa Wang
,
+5 authors
Gang Wang
Archives of medical science : AMS
2019
Corpus ID: 210967531
Introduction Aberrant expression of long non-coding RNAs (lncRNAs) has been implicated in various diseases, including cancer…
Expand
2018
2018
NUDCD1 promotes metastasis through inducing EMT and inhibiting apoptosis in colorectal cancer.
B. Han
,
Yuan-Yuan Zhang
,
+7 authors
Li-Ming Zhou
American Journal of Cancer Research
2018
Corpus ID: 47012820
Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the third leading cause of cancer death in both men and…
Expand
2014
2014
OVA66 increases cell growth, invasion and survival via regulation of IGF-1R-MAPK signaling in human cancer cells.
W. Rao
,
Haowen Li
,
+5 authors
H. Ge
Carcinogenesis
2014
Corpus ID: 15839367
Ovarian cancer-associated antigen 66 (OVA66), also known as CML66 (GenBank Accession No. AF283301), was first identified in an…
Expand
2011
2011
Structural features and chaperone activity of the NudC protein family.
Meiying Zheng
,
T. Cierpicki
,
+6 authors
Z. Derewenda
Journal of Molecular Biology
2011
Corpus ID: 23980879
2010
2010
Graft-versus-Leukemia Antigen CML66 Elicits Coordinated B-Cell and T-Cell Immunity after Donor Lymphocyte Infusion
Wandi Zhang
,
Jaewon Choi
,
+10 authors
Catherine J. Wu
Clinical Cancer Research
2010
Corpus ID: 9372842
Purpose: The target antigens of graft-versus-leukemia that are tumor associated are incompletely characterized. Experimental…
Expand
2008
2008
RNA interference targeting CML66, a novel tumor antigen, inhibits proliferation, invasion and metastasis of HeLa cells.
Qingfei Wang
,
Mei-xing Li
,
+8 authors
H. Ge
Cancer Letters
2008
Corpus ID: 41847800
2008
2008
Identification of an epitope derived from CML66, a novel tumor‐associated antigen expressed broadly in human leukemia, recognized by human leukocyte antigen‐A*2402‐restricted cytotoxic T lymphocytes
Koichiro Suemori
,
H. Fujiwara
,
+7 authors
M. Yasukawa
Cancer Science
2008
Corpus ID: 30088025
CML66 is a newly identified differentiation antigen that is expressed broadly in human leukemia and solid tumors, but its…
Expand
Highly Cited
2005
Highly Cited
2005
Graft-versus-Leukemia Target Antigens in Chronic Myelogenous Leukemia Are Expressed on Myeloid Progenitor Cells
Catherine J. Wu
,
M. Biernacki
,
+5 authors
J. Ritz
Clinical Cancer Research
2005
Corpus ID: 20800696
Purpose: Donor lymphocyte infusion (DLI) reliably induces durable remission in 75% to 80% of patients with relapsed chronic…
Expand
2004
2004
A Novel Mechanism of Alternative Promoter and Splicing Regulates the Epitope Generation of Tumor Antigen CML66-L1
Yan Yan
,
L. Phan
,
+9 authors
Xiaofeng Yang
Journal of Immunology
2004
Corpus ID: 30137537
This report describes the difference in the epitope generation of two isoforms of self-tumor Ag CML66 and the regulation…
Expand
Highly Cited
2001
Highly Cited
2001
CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia
Xiao-feng Yang
,
Catherine J. Wu
,
+8 authors
J. Ritz
Proceedings of the National Academy of Sciences…
2001
Corpus ID: 29917478
This report describes a tumor-associated antigen, termed CML66, initially cloned from a chronic myelogenous leukemia (CML) cDNA…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE